« Return to News | Awards & Advancement

Actinium Pharmaceuticals strengthens management team

Thursday, August 30, 2012 02:44 PM

Actinium Pharmaceuticals (API), a private biopharmaceutical company in New York that develops innovative targeted radio-immunotherapeutics, has strengthened its management team with the appointment of Jack V. Talley as president and CEO and Enza Guagenti as CFO.

Talley has more than 30 years of experience in marketing, drug development and regulatory matters. He is responsible for guiding two prior companies, Penwest Pharmaceuticals and EpiCept, through the transition to becoming public reporting entities, where until recently he served as president and CEO. Additionally, Talley oversaw the approval of Ceplene for the remission maintenance of acute myeloid leukemia in the E.U. as well as its license and eventual sale to Meda.

Guagenti is a CPA with over 25 years of experience in health care management financial oversight. Prior to assuming the role of CFO, she worked for API as a corporate accounting consultant for the past eight years. Guagenti has held senior management positions for various companies where she was responsible for operational and financial oversight and reporting, as well as compliance with state and federal regulatory bodies. Guagenti has also served on various state healthcare committees.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.